Mingjun Dong
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
-
- Circular RNAs in diseases
- Extracellular vesicles in disease
- Sphingolipid Metabolism and Signaling
- RNA modifications and cancer
Papers in
-
- Sphingolipid Metabolism and Signaling 3
- Extracellular vesicles in disease 2
- RNA modifications and cancer 2
-
- Cancer-related molecular mechanisms research 3
- MicroRNA in disease regulation 2
- Cancer, Hypoxia, and Metabolism 1
- Co-authors
- Yangyang Xie (8 shared papers)Xiaoyu Dai (6 shared papers)Yidong Xu (5 shared papers)Hua Yu (3 shared papers)Juan Xiao (4 shared papers)Junfei Jin (3 shared papers)Keqiang Li (4 shared papers)Jinhui Zhu (1 shared paper)
- Journals
- Scientific Reports (2 papers)Cancer Biology & Therapy (1 paper)Oncotarget (1 paper)Cancer Science (1 paper)Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Mingjun Dong
23 papers receiving 482 citations
Peers
Comparison fields: 5 of 82
- Cancer Research 149
- Molecular Biology 253
- Aquatic Science 25
- Microbiology 20
- Biochemistry 22
Countries citing papers authored by Mingjun Dong
This map shows the geographic impact of Mingjun Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingjun Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingjun Dong more than expected).
Fields of papers citing papers by Mingjun Dong
This network shows the impact of papers produced by Mingjun Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingjun Dong. The network helps show where Mingjun Dong may publish in the future.
Co-authors
The 25 scholars most cited alongside Mingjun Dong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 58 | |
| 2 | 2006 | 54 | |
| 3 | 2016 | 48 | |
| 4 | 2014 | 41 | |
| 5 | 2017 | 41 | |
| 6 | 2018 | 39 | |
| 7 | 2019 | 38 | |
| 8 | 2020 | 24 | |
| 9 | 2020 | 23 | |
| 10 | 2005 | 20 | |
| 11 | 2007 | 16 | |
| 12 | 2022 | 15 | |
| 13 | 2019 | 11 | |
| 14 | 2019 | 11 | |
| 15 | 2017 | 10 | |
| 16 | 2018 | 9 | |
| 17 | 2016 | 9 | |
| 18 | Serum sphingosine 1-phosphate in hepatocellular carcinoma patients is related to HBV infection. | 2019 | 6 |
| 19 | 2015 | 5 | |
| 20 | 2021 | 5 |
About Mingjun Dong
Mingjun Dong is a scholar working on Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine, Oncology and Cell Biology, having authored 24 papers that have together received 489 indexed citations. Recurring topics across this work include Sphingolipid Metabolism and Signaling (3 papers), Cancer-related molecular mechanisms research (3 papers), Aldose Reductase and Taurine (2 papers), Extracellular vesicles in disease (2 papers), MicroRNA in disease regulation (2 papers), RNA modifications and cancer (2 papers), Cancer, Hypoxia, and Metabolism (1 paper) and Nitric Oxide and Endothelin Effects (1 paper). The work is most often cited by research in Cancer Research (149 citations), Molecular Biology (253 citations), Aquatic Science (25 citations), Microbiology (20 citations) and Biochemistry (22 citations). Mingjun Dong has collaborated with scholars based in China and United States. Frequent co-authors include Yangyang Xie, Xiaoyu Dai, Yidong Xu, Hua Yu, Juan Xiao, Junfei Jin, Keqiang Li, Jinhui Zhu, Jianwei Wang and Tian Sun. Their work appears in journals such as Scientific Reports, Cancer Biology & Therapy, Oncotarget, Cancer Science and Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.